ImmunityBio, Inc. (IBRX) Stock: An Under $5 Gem with Biggest Upside Potential

Published on 21 Jan 2025 on Insider Monkey · via Yahoo Finance

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this...

Insider Monkey · via Yahoo Finance 21 Jan 2025

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the...

Zacks · via Yahoo Finance 17 Jan 2025

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this ...

Insider Monkey · via Yahoo Finance 17 Jan 2025

On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions...

Benzinga · via Yahoo Finance 17 Jan 2025

We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside...

Insider Monkey · via Yahoo Finance 14 Jan 2025

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In t...

Insider Monkey · via Yahoo Finance 23 Nov 2024

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated...

Benzinga · via AOL 25 Oct 2024

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated...

Benzinga · via Yahoo Finance 23 Oct 2024

We recently compiled a list of the 10 Best Fast-Growing Penny Stocks to Buy Now. In this article,...

Insider Monkey · via Yahoo Finance 21 Sep 2024

ImmunityBio’s IBRX commercial portfolio comprises its only marketed drug, Anktiva (N-803, or noga...

Zacks · via Yahoo Finance 20 Jun 2024